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Abstract 
Background: Dihydroartemisinin‑piperaquine (DHA‑PQ) is one of five WHO recommended artemisinin combination 
therapy (ACT) for the treatment of uncomplicated malaria. However, little was known on its post‑registration safety 
and effectiveness in sub‑Saharan Africa. DHA‑PQ provides a long post‑treatment prophylactic effect against re‑infec‑
tion; however, new infections have been reported within a few weeks of treatment, especially in children. This paper 
reports the clinical outcomes following administration of DHQ‑PQ in real‑life conditions in public health facilities in 
Burkina Faso, Ghana, Mozambique, and Tanzania for the treatment of confirmed uncomplicated malaria.
Methods: An observational, non‑comparative, longitudinal study was conducted on 10,591 patients with confirmed 
uncomplicated malaria visiting public health facilities within seven health and demographic surveillance system sites 
in four African countries (Ghana, Tanzania, Burkina Faso, Mozambique) between September 2013 and April 2014. 
Patients were treated with DHA‑PQ based on body weight and followed up for 28 days to assess the clinical outcome. 
A nested cohort of 1002 was intensely followed up. Clinical outcome was assessed using the proportion of patients 
who reported signs and symptoms of malaria after completing 3 days of treatment.
Results: A total of 11,097 patients were screened with 11,017 enrolled, 94 were lost to follow‑up, 332 withdrew and 
10,591 (96.1 %) patients aged 6 months–85 years met protocol requirements for analysis. Females were 52.8 and 
48.5 % were <5 years of age. Malaria was diagnosed by microscopy and rapid diagnostic test in 69.8 % and 29.9 %, 
respectively. At day 28, the unadjusted risk of recurrent symptomatic parasitaemia was 0.5 % (51/10,591). Most of the 
recurrent symptomatic malaria patients (76 %) were children <5 years. The mean haemoglobin level decreased from 
10.6 g/dl on day 1 to 10.2 g/dl on day 7. There was no significant renal impairment in the nested cohort during the 
first 7 days of follow‑up with minimal non‑clinically significant changes noted in the liver enzymes.
Conclusion: DHA‑PQ was effective and well tolerated in the treatment of uncomplicated malaria and provides an 
excellent alternative first‑line ACT in sub‑Saharan Africa.
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Background
Artemisinin-based combination therapy (ACT) is highly 
effective for the treatment of uncomplicated falciparum 
malaria with five formulations, including dihydroarte-
misinin (DHA) and piperaquine (PQ) combination cur-
rently recommended by the World Health Organization 
(WHO) [1]. ACT has been adopted as first-line treatment 
in 79 of 88 countries where Plasmodium falciparum is 
endemic as at 2013 [2].
The different modes of action of the partner drugs con-
tribute to the efficacy of ACT. These partner drugs (e.g., 
PQ, mefloquine, amodiaquine, lumefantrine, pyronari-
dine) are eliminated slowly compared to the artemisinin 
derivatives (e.g., DHA, artesunate, artemether), which 
are eliminated rapidly, although they swiftly bring down 
the parasite biomass [3]. This provides protection for the 
artemisinin derivative while the partner drugs provide 
prolonged drug cover [4].
The half-life of PQ is 21–28  days [5–7], longer than 
most of the partner drugs used in ACT, providing a 
longer post-treatment prophylactic effect compared to 
lumefantrine (3–5  days) [3, 8], the active amodiaquine 
metabolite desethylamodiaquine (7–12  days) [9], meflo-
quine (17–24  days) [10], and pyronaridine (13.2 and 
9.6  days in adults and children, respectively) [11]. The 
long half-life of PQ has an important role in prevent-
ing re-infection or recrudescence. It may also contrib-
ute to recovery of decreased haemoglobin (Hb), which 
has been observed in the pathogenesis of malaria espe-
cially on days 3 and 7, although in a majority of patients 
Hb recovery to normal levels occurs on day 28 [12]. 
Pooled analysis of seven randomized, controlled tri-
als on ACT, including Dihydroartemisinin-piperaquine 
(DHA-PQ) from 14 sub-Saharan African sites of 3044 
children ≤5 years showed a decline in Hb levels on day 7 
with recovery between days 14–28 [13].
Despite the longer half-life of PQ, new infections have 
been reported within a few weeks of treatment with 
DHA-PQ, particularly in children age 2–10 years because 
of their higher body weight-normalized clearance. This 
leads to lower PQ exposure compared to older per-
sons with lower day 7 PQ concentrations after standard 
weight-based dosing [14, 15]. This effect has been asso-
ciated with an increased risk of recurrent parasitaemia 
[14].
Pooled analysis of 14 studies published in 13 articles 
(11 in Southeast Asia, one in China and one in Rwanda) 
involving 2636 patients on DHA-PQ from 2002 to 2006 
found it to be safe and highly effective in the treatment of 
uncomplicated falciparum malaria [16] and comparable 
to other ACT [14, 17, 18]. Treatment with DHA-PQ in 
Africa has shown a lower risk of recurrent malaria com-
pared to artesunate and amodiaquine combination (AS/
AQ) [19] and artemether and lumefantrine combination 
(AL) [18, 20] but some studies showed no significant pro-
phylactic effect in comparison to AL [21].
This study evaluated the clinical outcomes of DHQ-
PQ when administered under real-life conditions for the 
treatment of confirmed uncomplicated malaria in public 
health facilities in Burkina Faso, Ghana, Mozambique, 
and Tanzania as part of a larger study conducted to assess 




This was an observational, non-comparative, longitudinal 
study in patients with signs and symptoms of uncompli-
cated malaria confirmed by a parasitological diagnosis 
or, when the tests were not available, by WHO diagnos-
tic criteria in seven health and demographic surveillance 
system (HDSS) sites in four sub-Saharan African coun-
tries from September 2013 to April 2014. The detailed 
study design together with the safety profile has been 
published elsewhere [22].
Study sites
The seven study sites are part of eight HDSS INDEPTH 
Effectiveness and Safety (INESS) platforms established 
since 2009 with Bill and Melinda Gates Foundation fund-
ing. The sites are Dodowa, Kintampo and Navrongo in 
Ghana, Nanoro and Nouna in Burkina Faso, Manhiça in 
Mozambique, and Rufiji in Tanzania. The other member 
site is Ifakara in Tanzania. They are all members of WHO 
Programme for International Drug Monitoring with 
spontaneous and cohort event monitoring on anti-malar-
ials, alongside their routine, longitudinal, health and 
demographic surveillance data gathering [22]. Estimated 
total population of these seven HDSS sites is 752,937 
[23]. Malaria is endemic in all the study sites with vary-
ing transmission due to different geographical conditions 
and rainfall patterns. P. falciparum is responsible for the 
majority of malaria cases at these sites. Anopheles gam-
biae and A. funestus are the main vectors. AS/AQ and 
AL are first-line ACT for the treatment of uncomplicated 
malaria, with only Ghana having DHA-PQ as the third 
Keywords: Dihydroartemisinin‑piperaquine, Uncomplicated malaria, Artemisinin‑based combination therapy, 
Treatment outcome, Effectiveness
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first-line. Detailed profiles of the study sites are published 
elsewhere [24–30].
Recruitment process
Patients with confirmed uncomplicated malaria were 
recruited from the outpatient departments of selected 
public health facilities in the seven HDSS sites. The inclu-
sion criteria were age ≥6 months, weight ≥5 kg, ability to 
tolerate oral medications, and willingness to participate 
based on signed informed consent. Malaria was diag-
nosed as per the national policies in the four countries 
in line with WHO recommendations [history of fever in 
the previous 24 h or presence of fever and parasitologi-
cal confirmation by microscopy or rapid diagnostic test 
(RDT)]. The exclusion criteria included: known allergy to 
artemisinin or to PQ; history of taking a DHA-PQ dose 
in the previous 4  weeks, known pregnancy, lactating 
women, complicated malaria, history of taking medici-
nal products that are known to prolong the corrected 
QT (QTc) interval on echocardiogram (ECG) (including 
anti-arrhythmics, neuroleptics and certain antimicrobial 
agents), and family history of sudden unexplained death 
or personal/family history of predisposing cardiac condi-
tions for arrhythmia/QT prolongation. Patients or their 
guardians were encouraged to comply with all scheduled 
follow-up visits.
Main group and nested cohort
Patients were recruited into two groups, the main and 
nested cohort with no special criteria apart from the 
stated inclusion and exclusion criteria. Sites determined 
the cohort criteria based on their follow-up plan. Each 
eligible patient had a detailed clinical assessment includ-
ing past medical and drug history after a confirmed para-
sitological (microscopy and RDT) diagnosis. Capillary 
blood sample was used in preparing thick blood smear 
and parasite density calculated per 200 leucocytes. The 
sites used different HRP2-based RDTs with sensitivity 
ranging from 90.5–99.7 % for P. falciparum, 92.9–95.5 % 
for non-P. falciparum and specificity of 97.5–99.5 %.
Nested cohort laboratory procedure
A detailed laboratory assessment beside a prerequisite 
confirmed microscopic parasitaemia at baseline was car-
ried out for the nested cohort. Investigations carried out 
were haematology (white cell count with differentials, red 
blood cells, Hb level and platelet count), biochemistry 
[total bilirubin, alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), creatinine, urea, serum 
potassium and chloride], and plasma concentration of 
PQ as well as triplicate baseline ECG before day 1 drug 
administration. On each visit, 5 ml of venous blood was 
used for the investigations. Different types of Sysmex 
(Poch 100i, KX-2IN, XT 20090i) and ABX micros B were 
used for haematology at the various sites while Selec-
tra Junior, Humalyzer primus with Integra 400 plus and 
Vitalab flexor E were used for biochemistry analysis of 
patient samples.
Drug administration
Eurartesim® (DHA-PQ) was administered once daily 
based on body weight for 3  days. Two concentrations 
were used: 20/160 and 40/320  mg of DHA and PQ, 
respectively, as shown in Table  1. Drugs were admin-
istered under direct observed therapy (DOT) on the 
first day for all patients and for the 3 days in the nested 
cohort. Drug was administrated with water and patients 
observed for an hour in case of vomiting and any other 
adverse events (AEs). Those who vomited within 30 min 
were re-administered the full dose and those who vom-
ited after 30 min but within the hour were given half of 
the dose. Re-dosing was done once and rescue treat-
ment given for unsuccessful re-dosing as per the specific 
national guidelines. Patients were encouraged to com-
plete the treatment, avoid high fatty or calorie diets 3 h 
before and after dosing. Paediatric doses were however 
crushed and administered with water.
Follow‑up procedure
Patients were followed up for 28  days with active fol-
low-up on day 5 (±2  days) and day 28 by telephone or 
Table 1 Drug concentrations
Body weight (kg) Daily dosage (mg) Number of tablets per dose
20/160 mg DHA‑PQ 40/320 mg DHA‑PQ
5 to <7 10 mg DHA and 80 mg PQ 1/2 tablet
7 to <13 20 mg DHA and 160 mg PQ 1 tablet
13 to <24 40 mg DHA and 320 mg PQ 1 tablet
24 to <36 80 mg DHA and 640 mg PQ 2 tablets
36 to <75 120 mg DHA and 960 mg PQ 3 tablets
75 to <100 160 mg DHA and 1280 mg PQ 4 tablets
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physical contact to document recovery status and AEs. 
Compliance to treatment was assessed in the main group 
by asking if patient adhered to the study prescription on 
day 5 (±2 days). The nested cohort was additionally fol-
lowed on days 2, 3 and 7. Day 2 visit was at home, for 
DOT of the second dose of the study medication, moni-
tor clinical status and record any AEs. Patients were seen 
at the health facilities on day 3 for treatment completion, 
ECG recording (single pre and 3- to 4-hour triplicate 
post dosage) and then repeat haematology, biochemistry 
and plasma PQ concentration. These investigations were 
repeated on day 7 with a single ECG recording. Each 
facility visit included detailed clinical workup, screening 
for AEs and appropriate case report forms were com-
pleted. Patients were also encouraged to report any AEs 
experienced from day 1 to day 28 by telephone or visit to 
the health facility (unscheduled visit). Patients with signs 
and symptoms of malaria on all unscheduled visits were 
re-tested for malaria and managed appropriately as per 
national guidelines.
Outcome
The primary outcome of interest was adequate clinical 
response at day 28, defined as absence of clinical signs 
and symptoms for malaria at day 28. Treatment failure 
was defined as unresolved symptoms and signs and para-
sitaemia within 2  weeks of full treatment or recurrence 
of fever and parasitaemia after 2 weeks of full treatment 
[1]. The definition was used to estimate the rate of unad-
justed recurrent symptomatic parasitaemia. Second-
ary outcomes included the prevalence of fever, change 
in mean Hb levels, mean bilirubin levels, liver enzymes, 
and renal function on the nested cohort during the first 
7 days of follow-up.
Data entry and statistical analysis
Data were double-entered using Open Clinica software 
from all sites. Statistical analyses were performed using 
the software package STATA® (version 11.2). Descrip-
tive analysis of all data recorded at study entry was car-
ried out to characterize the population studied. The main 
outcome of interest, frequencies and respective percent-
ages were calculated. Proportions, means and standard 
deviations were used in estimating the secondary out-
comes. Means were estimated for other continuous inde-
pendent variables. The parasite densities were grouped 
as <500 parasites/µL, 500 to <5000 parasites/µL and 5000 
parasites/µL and above.
Ethics statement
The Institutional Ethics Committee of all seven HDSS 
sites involved in the trial and the Independent National 
Ethics Review Committees in these four countries 
approved the protocol. The protocol and case report 
forms are available and annexed as supporting docu-
ments. The study was conducted in accordance with 
Good Clinical Practice and the Helsinki declaration for 
biomedical research on human subjects. The Safety Com-
mittee, Central Data Monitoring Team and Independent 
Monitors provided oversight of study conduct. The study 
was registered with Clinicaltrials.gov; Trial registration 
number NCT02199951.
Results
A total of 10,591 participants successfully completed 
the study and were included in the analysis (Fig. 1). The 
age distribution was 6  months–85  years with a median 
of 8  years. About 53  % (5068) of the participants were 
females and 48.4  % (4654) children  <5  years of age. 
Patients were recruited at three HDSS sites in Ghana, 
two in Burkina Faso and one each in Tanzania and 
Mozambique. Manhiça site had the highest recruitment 
of 18.6  % (1965) with Dodowa site recruiting the least, 
8.4 % (884). The highest recruitment in the nested cohort 
and the main group were 27.4 % (274) and 19.6 % (1876) 
from Navrongo and Manhiça sites, respectively (Table 2).
The mean weight and height for the main group were 
26.0  kg and 117.2  cm, and that for the nested cohort 
were 28.7  kg and 125.5  cm, respectively. Weight and 
height measurements were taken on day 1. The mean 
temperature for both cohorts on day 1 was 37.4  °C and 
declined to 36.6  °C on day 7 for the nested cohort. Out 
of the 1002 patients in the nested cohort, 441 had tem-
perature  ≥37.5  °C on day 1. This decreased to 35 and 
39 patients on day 3 and day 7, respectively. Forty-three 
per cent (4104) of the main group had fever on day 1. 
With the exception of blood pressure, all other vital 
signs decreased with age and no significant change was 
recorded among the nested cohort within the first 7 days 
of follow-up.
Laboratory results
Malaria diagnosis was confirmed by microscopy and RDT 
in 69.8 % (7391) and 29.9 % (3170) patients, respectively, 
with 30 patients diagnosed clinically. The RDTs were P. 
falciparum cases. There were 94 cases of mixed infections 
from the microscopic findings: 90 of P. falciparum and P. 
malariae and four of P. falciparum and P. ovale with no 
case of P. vivax reported. Gametocyte carriage was 2.7 % 
(199/7260) and 11.1 % (13/117) for P. falciparum and P. 
malariae cases, respectively, by microscopy. Majority of 
patients had parasitaemia <5000/µL (Table 3).
Haematology results for nested cohort (n = 1002)
The mean Hb of the nested cohort decreased from 
10.6  g/dl on day 1 to 10.2  g/dl on day 7, however, it 
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increased by 0.2 g/dl from day 3 to day 7 (Fig. 2). A total 
of 33 % (326) of patients had anaemia (Hb <10 g/dl) on 
day 1 with one having severe anaemia (Hb 4.6 g/dl). Even 
though this patient should not have been enrolled as per 
the protocol, the Hb remained between 4.5 and 4.6 g/dl 
from enrolment to day 7. The number of patients with 
anaemia increased to 47 % (471) and 43 % (431) on days 
3 and 7, respectively. Seventy-five per cent or more of 
patients had Hb of ≥8 g/dl on days 1 (77 %), 3 (75 %) and 
7 (77 %). A total of 17 % (174) and 16 % (159) patients had 
a decline in Hb to levels ≤10 g/dl on days 3 and 7, respec-
tively, despite being ≥10 g/dl on day 1.
11, 097 Participants screened  
(Patients with uncomplicated malaria)
Withdrawn (n=332)
Loss to follow up (n=94)
Unscheduled Visit: 346 participants, 
214 tested for malaria
Eligible (N=10591)
Ghana:  4,563 (43%)




Participants: 1002 (9%) 
General Group 
Participants: 9589 (91%) 
Excluded (n=80)
Visit beyond 




only for either RDT 






Visit within 28 days of 
follow up: 51
Visit within 2weeks of 
completing treatment: 24
Visit after 2weeks of 
completing treatment: 27
11, 017 were successfully 
recruited 
Malaria Test 
Positive for RDT 
but Negative for 
microscopic): 54
Fig. 1 Study flow chart
Page 6 of 10Adjei et al. Malar J  (2016) 15:43 
Clinical chemistry results for nested cohort (n = 1002)
There was no significant liver or renal impairment in 
the nested cohort with the mean values decreasing from 
day 1 to day 7 (Table 4). A total of 345 patients who were 
enrolled had bilirubin levels  >18  μmol/L on day 1 with 
one patient having 174.9  μmol/L. Out of these, 87  % 
(299/345) had their bilirubin levels decreased below the 
upper limit (18  μmol/L) on day 7. In all, 76 patients on 
day 7 still had elevated bilirubin levels with maximum 
value recorded being 71.3 μmol/L and 28 % (21/76) had 
levels twice the upper limit. ALT and AST mean levels 
were all within normal (<40 U/L), however, 150 and 164 
patients had their baseline ALT and AST values higher 
than 40  U/L, respectively, on day 1. Of these patients, 
67  % (101/150) and 64  % (105/164) had their ALT and 
AST levels return to normal on day 7, respectively. 
However, there were 68 and 49 patients who had nor-
mal ALT and AST levels (<40 U/L), respectively, on day 
1 but higher than normal on day 7. The total number of 
patients with elevated ALT and AST levels on day 7 were 
115 and 106 patients, respectively. Notably, 17 % (19/115) 
and 12 % (13/106) had levels higher than twice the upper 
limit of 40 U/L on day 7. Measured mean blood urea lev-
els decreased from day 1 to day 7 while there was a mar-
ginal increase of 1.1 in mean creatinine level from day 1 
to day 3 and then a decrease by 2.2 on day 7 (Table 4).
Unscheduled visits by patients with clinical signs 
and symptoms
A total of 346 patients came for unscheduled visits of 
which 16 had a repeat visit (unscheduled visit two) from 
day 4 to day 28. Fever, cough, headache, abdominal pains, 
and anorexia were the common symptoms presented 
on these visits (Fig.  3). Of the unscheduled visits 65  % 
(214/330) had malaria test done by microscopy, RDT 
or both methods. Of those tested, 24  % (51/214) were 
positive for malaria (24 RDT or 19 microscopy or eight 
from both methods) and 25 % (54/214) as false positive 
(RDT positive but microscopic negative). Majority of the 
patients who tested positive (48/51) were in the main 
group with only two patients yet to complete day-3 dos-
age when contacted on day 5 (±2 days) follow-up. They 
were treated with AS/AQ (14/51), AL (19/51), quinine 
(7/51), and no anti-malarial treatment (11/51). Of the 
patients who received no treatment, 73 % (8/11) sought 
care within 2  weeks from day of enrolment and even 
though still tested positive by RDT, they were treated 
for acute respiratory infections (ARI) and gastroenteritis 
based on other symptoms and signs presented.
Table 2 The demographic characteristics of  the recruited 
participants from the seven HDSS sites






 6–11 months 327 (3.4) 6 (0.6) 333 (3.1)
 12–59 months 4327 (45.1) 325 (32.4) 4652 (43.9)
 Above 
59 months
4935 (51.5) 671 (67.0) 5606 (52.9)
Enrolment
 Eligible 9589 (98.0) 1002 (76.2) 10,591 (95.4)
 Excluded 68 (0.7) 12 (0.9) 80 (0.7)
 Withdrawn 125 (1.3) 301 (22.9) 426 (3.8)
Sex
 Male 4521 (47.2) 489 (48.2) 5004 (47.3)
 Female 5068 (52.8) 518 (51.7) 5586 (52.7)
Country/site
 Burkina faso 3017 (28.5)
 Nouna 1658 (17.3) 102 (10.2) 1760 (16.6)
 Nanoro 1060 (11.1) 197 (19.7) 1257 (11.9)
 Ghana 4563 (43.1)
 Dodowa 729 (7.6) 155 (15.6) 884 (8.4)
 Kintampo 1763 (18.4) 15 (1.5) 1778 (16.8)
 Navrongo 1627 (17.0) 274 (27.4) 1901 (17.9)
 Mozambique 1965 (18.6)
 Manhiça 1876 (19.6) 89 (8.9) 1965 (18.6)
 Tanzania 1046 (9.9)
 Rufiji 876 (9.1) 170 (17.0) 1046 (9.9)
Table 3 Malaria parasites species determined by microscopy
The nested cohort total is more than the 1002 because of mixed infections
Parasites density (/µL) Plasmodium species n (%)
P. falciparum P. ovale P. malariae
Total Nested Total Nested Total Nested
7260 (98.2) 995 14 (0.2) 3 117 (1.6) 25
<500 1949 (26.8) 302 3 (21.4) 0 52 (44.4) 11
500 to <5000 2028 (27.9) 265 10 (71.4) 3 60 (51.3) 13
≥5000 3283 (45.2) 428 1 (7.1) 0 5 (4.3) 1
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Primary outcome
By day 28 the unadjusted risk of recurrent sympto-
matic parasitaemia was 0.5  % (51/10,591). Of these, 
47  % (24/51) were seen within 2  weeks of treatment 
(4–14  days) (median 7.7  days) and 53  % (27/51) after 
2  weeks of treatment (15–28  days) (median 21  days). 
Most patients 76 % (39/51) with recurrent symptomatic 
parasitaemia were <5 years. Navrongo, Nouna and Rufiji 
sites recorded 80  % (33, 18 and 29  %, respectively) of 
these cases as shown in (Fig. 4). Using univariate analy-
sis, temperature at first presentation, age and some of 
the study sites were significantly associated with treat-
ment failure. A 1  °C increase in temperature was 13  % 
more likely to lead to treatment failure (OR I.13, CI 95 %, 
0.88–1.45). Patients aged >5 years were 27 % (OR 0.27, CI 
95 %, 0.14–0.52) less likely to develop treatment failure as 
compared to <5 years. Patients recruited from Navrongo, 
Rufiji and Nouna sites were eight, 13 and five times more 
likely to have treatment failure than those recruited from 
Dodowa site, respectively (OR 7.97, CI 95 %, 1.06–59.96; 
OR 12.85, CI 95 %, 1.69–97.45; OR 4.54, CI 95 %, 0.57–
35.88). Being in the main group was 60  % (OR 0.60, CI 
95 %, 0.16–1.92) more likely to develop treatment failure 
compared to those in the nested cohort. After adjust-
ing for demographic factors, clinical presentation and 
baseline parasitaemia: age (>5  years) and one study site 
(Rufiji) were significantly associated with treatment 
failure (OR 0.30, CI 95  %, 0.15–0.58; OR 8.49, CI 95  %, 
1.10–65.47).
Discussion
In this large-scale, phase IV study of DHA-PQ (Eurar-
tesim) administration in ‘real-life clinical situations’ at 
public health facilities for the treatment of confirmed 
uncomplicated malaria, WHO acceptable (>95  %) ade-
quate clinical response with very low unadjusted rate of 
recurrent symptomatic parasitaemia of 0.5  % by day 28 
was observed. This rate is lower than previously observed 
in more controlled studies in Southeast Asia [16] and 
sub-Saharan Africa [18, 19, 31] but may be due to the 
fact that non-symptomatic parasitaemia was not sought. 
However, this is a reflection of routine clinical care and 
emphasizes the fact that true treatment outcomes are not 
best measured under safety studies but rather through 
well-designed efficacy clinical trials.
This study found that the majority of the recurrent 
symptomatic parasitaemia occurred almost in equal pro-
portions within 14 days and after 14 days’ post-treatment. 
This is in contrast to the review of 39 trials on ACT in 
the WHO 2010 treatment guidelines, which had enrolled 
6124 participants. No treatment failure was recorded 
within two weeks in 32 of the trials. In the remaining 
seven trials, failure rates at day 14 ranged from 1–7  %, 
highlighting unusual rate of treatment failure within 
2 weeks of treatment [1]. This could be due to PCR-cor-
rected cure rates and also the well-documented, longer, 
post-treatment prophylactic effect of DHA-PQ because 
of the longer half-life of PQ [5–7] and relatively short fol-
low-up of 28 days in this study. The high treatment fail-
ure rates recorded in Navrongo and Rufiji could be due 






















Fig. 2 Mean haemoglobin level (g/dl) in the nested cohort 
(n = 1002)
Table 4 Biochemistry results for the nested cohort (n = 1002)
Variable (unit) Day 1 Day 3 Day 7
Mean (SD) n (%) Mean (SD) n (%) Mean (SD) n (%)
Bilirubin (μmol/L) 17.8 (15.0) 995 (99.3) 8.8 (8.0) 994 (99.2) 9.2 (8.1) 1000 (99.8)
ALT (U/L) 28.9 (28.8) 997 (99.5) 27.3 (28.5) 995 (99.3) 27.7 (24.4) 1000 (99.8)
AST (U/L) 31.1 (36.4) 1000 (99.8) 29.0 (30.3) 997 (99.5) 27.9 (21.2) 1001 (99.9)
Creatinine (μmol/L) 52.0 (30.2) 990 (98.8) 53.1 (32.5) 984 (98.2) 50.9 (29.4) 994 (99.2)
Urea (mmol/L) 4.9 (3.9) 997 (99.5) 4.3 (3.9) 983 (98.1) 4.1 (4.1) 998 (99.6)
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compared to other sites, particularly Dodowa. The inten-
sive follow-up in the nested cohort (DOT on the 3 days) 
clearly showed in the number of patients (3/51) who had 
treatment failure and this emphasizes the importance of 
drug adherence.
The majority of treatment failure cases were found in 
the  <5 age group corroborating earlier reports [14]. In 
younger patients it has been documented that they may 
have a lower exposure to PQ drug level at current dosing, 
predisposing them to recurrent parasitaemia in DHA-PQ 
studies [14, 15]. Documented evidence from the World-
wide Antimalarial Resistance Network (WWARN) DHA-
PQ Study Group showed that increasing the minimal 
dosage of PQ in <5 years reduces the risk of treatment fail-
ure [32]. This has led to the revised dose recommendation 
by WHO in the 2015 treatment guideline for malaria in 
children with weight <25 kg [33]. The recurrent parasitae-
mia in the younger age group could also be due to the lack 








































Fig. 4 Distribution of recurrent symptomatic parasitaemia cases 
among the seven sites
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This study reveals DHA-PQ to be very well tolerated with 
excellent adherence because of the simple daily dosing, as 
previously described [16, 31]. Other studies in some parts 
of Africa have documented the excellent efficacy of DHA-
PQ with good tolerability, prolonged prophylactic effect 
and once daily dosage, making it an excellent ACT for 
high transmission zones [14].
Of the 51 patients who tested positive during the 
unscheduled visit, 22  % (11/51) were not treated with 
an anti-malarial contrary to the WHO malaria treat-
ment guideline [1]. The reason for the non-treatment of 
these patients, the majority (73 %) of whom were within 
2  weeks of treatment and still tested positive by RDT, 
was because of the long clearance time of the RDTs used. 
They were treated for other presenting conditions (ARI 
and gastroenteritis). The HRP2-based RDT is known to 
remain positive within 2  weeks of treatment, or some-
times more, after effective treatment because of the per-
sistence of malaria antigens [34] leading to false positive 
test. A limitation of this study was not microscopically 
confirming all recurrent symptomatic cases because of 
the possibility of false positive from RDT only, but this 
is what happens in real-life situations where different 
WHO-recommended diagnostic methods are used.
The mean Hb outcome on day 7 was lower than the 
baseline level. This confirms similar results by Tjitra 
et  al. [12] and Olliaro et  al. [13], and can be attributed 
to disease pathogenesis with loss of infected and malaria 
antigen-coated red blood cells during treatment and 
recovery. The long half-life of PQ, which is known to pre-
vent relapse or re-infection, has also been suggested to 
contribute to the recovery from anaemia together with 
many other factors [12]. Some studies have reported 
increase in Hb levels from day 7 to 28 after ACT [35]. The 
mean values of the clinical chemistry parameters were 
within normal reference ranges and further decreased 
during the first seven days of follow-up, which is compa-
rable to other studies [13]. There were patients who were 
observed to have recorded values higher on day 7 than 
the baseline and vice versa. It will be difficult to attrib-
ute these observed changes only to the drug, knowing the 
well-documented effect of malaria parasites on the liver 
and kidney [36, 37] and possibility of co-infections, espe-
cially viral.
Conclusion
This is the largest phase IV study in sub-Saharan Africa 
on DHA-PQ for the treatment of uncomplicated malaria, 
showing that DHA-PQ is very effective and tolerable. 
DHA-PQ should be an appropriate alternative to other 
first-line ACT in sub-Saharan Africa and its deployment 
will reduce drug pressure on the two widely used ACT 
(AS/AQ and AL).
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